| Filed On | Filing |
|---|---|
| 03 Sep 2026 |
8-K/A: Financial Statements and Exhibits
Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and liabilities related to its GMP manufacturing operations (the "Purchased Assets"), including it... |
| 07 Aug 2015 |
8-K/A: Results of Operations and Financial Condition
ROCKVILLE, Md., August 5, 2015 – MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as... |
Loading...